Education
About Us
Working with TipRanks
Follow Us
CapsoVision, Inc. (CV)
NASDAQ:CV
CV Stock Chart & Stats
$13.23
--
Market closed
$13.23
--
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)45.47K
Market Cap
$257.17M
Enterprise Value$240.36M
Total Cash (Recent Filing)$17.79M
Total Debt (Recent Filing)$978.00K
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding46,843,224
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-1.04
Price to Sales (P/S)11.50
P/FCF Ratio-6.68
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue24.94
Enterprise Value/Gross Profit46.05
Enterprise Value/Ebitda-13.71
Forecast
1Y Price Target
$14.00Price Target Upside5.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$19.22M
Bulls Say, Bears Say
Bulls Say
FDA 510(k) Submission For AI ModuleA 510(k) submission for an AI-assisted reading module is a structural product development that, if cleared, enables U.S. commercialization of workflow‑reducing software. Clearance would cement a scalable software offering that complements capsule sales and can sustainably improve adoption and unit economics.
Breakthrough Device Designation PursuitSeeking Breakthrough Device status targets expedited development and regulatory engagement for early pancreatic cancer detection. If granted, it can shorten time-to-market, improve clinician adoption, and create a durable clinical differentiation addressing an unmet diagnostic need with potential long-term clinical and commercial implications.
Recurring Consumable + Software Revenue ModelA business model centered on disposable imaging capsules plus software and services creates recurring revenue potential and predictable unit demand. Over time, consumable-driven workflows can provide steady revenue streams and higher lifetime value per customer if clinical adoption and reimbursement trends hold.
Bears Say
Negative Stockholders' EquityNegative shareholders' equity is a durable solvency concern: it signals liabilities exceed assets, limits borrowing capacity, can constrain supplier and customer confidence, and reduces strategic flexibility. Without sustained profitability or capital support, growth and R&D programs are at persistent risk.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow undermines the company's ability to self-fund commercialization and product development. Over months, continued cash burn increases dilution or financing dependency, complicates long-term planning, and raises execution risk for regulatory and commercial milestones.
Unprofitable With Declining MarginsRevenue growth paired with worsening margins and sizable losses indicates structural cost or pricing issues. If inefficiencies persist, the company may struggle to translate clinical/regulatory wins into sustainable profitability, requiring material operational restructuring or continued external capital over the medium term.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $257.17M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 164 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.046.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Undervalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 46,843,224 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went down -9.7%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
CapsoVision, Inc.
CapsoVision, Inc. (CV) is a pioneering company in the medical technology sector, specializing in the development of innovative gastrointestinal imaging solutions. The company focuses on enhancing patient care through its flagship product, the CapsoCam, a capsule endoscopy system designed to provide high-quality images of the gastrointestinal tract with minimal discomfort for patients. CapsoVision aims to improve diagnostic capabilities and patient outcomes by leveraging advanced imaging technologies and a commitment to continuous innovation in the field of gastrointestinal health.
CV Earnings Call
Q3 2025
0:00 / 0:00
CV Stock 12 Month Forecast
Average Price Target
$14.00
▲(5.82% Upside)
Technical Analysis
Ownership Overview
2.92% Insiders
0.40% Mutual Funds
― Other Institutional Investors
96.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---